Thus, in a patient treated with radiotherapy and a NK-1R antagonist (aprepitant, 1140 mg/day for 45 days), the tumor mass disappeared after six months and no serious side-effects were observed [50], and in patients with cancer, the efficacy (promoting apoptosis) of targeted alpha therapy with 213Bi-DOTA-SP (radionuclide tumor therapy) against tumor cells has been reported [51,52,53,54,55]. This evidence concerns the gene TACR1 and cancer.